Eliem Therapeutics Appoints New CMO, Directors

TL;DR

Eliem Therapeutics beefs up leadership with a new CMO and two board members.

AI Summary

Eliem Therapeutics, Inc. announced on June 12, 2024, the appointment of Dr. Andrew R. Haskins as Chief Medical Officer and the election of Dr. Sarah L. Hough and Mr. David M. Gryfe to its Board of Directors. The company also disclosed compensatory arrangements for its officers.

Why It Matters

Changes in key leadership roles and board composition can signal strategic shifts or new directions for a biotechnology company focused on developing therapies.

Risk Assessment

Risk Level: medium — Appointments of new officers and directors, along with compensatory arrangements, can introduce new strategic directions or potential changes in operational focus.

Key Players & Entities

• Eliem Therapeutics, Inc. (company) — Registrant
• Dr. Andrew R. Haskins (person) — Appointed Chief Medical Officer
• Dr. Sarah L. Hough (person) — Elected to Board of Directors
• Mr. David M. Gryfe (person) — Elected to Board of Directors
• June 12, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share ELYM The Nasdaq Stock Mar
• $650,000 — . Brennan will be paid a base salary of $650,000 per year. Dr. Brennan will also be elig

Filing Documents

• d839370d8k.htm (8-K) — 56KB
• d839370dex101.htm (EX-10.1) — 64KB
• g839370g0612083357697.jpg (GRAPHIC) — 5KB
• 0001193125-24-159994.txt ( ) — 274KB
• elym-20240612.xsd (EX-101.SCH) — 3KB
• elym-20240612_lab.xml (EX-101.LAB) — 18KB
• elym-20240612_pre.xml (EX-101.PRE) — 11KB
• d839370d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: completion of the proposed Acquisition, the transactions contemplated by the Acquisition and the expected management team and board of directors of Post-Closing Eliem. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with completion of the proposed Acquisition in a timely manner or on the anticipated terms or at all; the satisfaction (or waiver) of closing conditions to the consummation of the Acquisition, including with respect to the approval of Eliem's and Tenet's stockholders; risks related to Eliem's and Tenet's ability to estimate their respective operating expenses and expenses associated with the transaction; uncertainties regarding the impact any delay in the closing would have on the anticipated cash and cash equivalents of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash and cash equivalents; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Acquisition Agreement; the effect of the announcement or pendency of the Acquisition on Eliem's or Tenet's business relationships, operating results and business generally; the ability of the combined company to timely and successfully achieve or recognize the anticipated benefits of the Acquisition; the outcome of any legal proceedings that may be instituted against Eliem or Tenet following the announcement of th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Eliem Therapeutics, Inc. Date: June 12, 2024 By: /s/ Andrew Levin Andrew Levin, M.D., Ph.D. Executive Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR